Equity Field Notes from temporal sources

[DanWebzster]

RIGL (update)

FDA approved Fostamatib for Chronic Immune Thrombocytopenic Purpuri 4/18.

Fostamatib could eventually become a $1B drug if it is approved in all of its indications. That is the bull case. The bear case revolves around the competition that may evolve in its other indications.

Fostamatib is now in Ph2 for warm Autoimmune Hemolytic Anemia (AIHA). This open label study should complete 6/19. There are other competing in this indications, not the least of which is a compound in Ph2 being developed by INCY

Fostamatib is also being studied in IgA Nephropathy where it competes with a promising compound being developed by OMER as well as compounds by RETA and RTRX.

Cash runway extends to Q4/19